Back to results
US 2020/0345744 A1Published application
Treatment of tachycardia
AssigneeOslo University Hospital HF
InventorsJan Magnus ARONSEN, Jonas SKOGESTAD
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeOslo University Hospital HF
InventorsJan Magnus ARONSEN, Jonas SKOGESTAD
Estimating the term…
The invention provides compounds which are selective PDE2 inhibitors for use in the treatment of tachycardia or tachyarrhythmia Such compounds are particularly suitable for use in the treatment of any of the following conditions: atrial tachycardia, atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia, premature ventricular contractions (PVCs), ventricular fibrillation and ventricular tachycardia, and may be used alone or in combination therapy with other conventional cardiovascular drugs, e.g. beta-blockers. In particular, the invention provides compounds which are selective PDE2 inhibitors for use in the treatment of ventricular tachycardia in patients who are suffering from, or who are at risk of suffering from heart failure, CPVT or long QT syndrome.
A compound which is a selective PDE2 inhibitor for use in the treatment or prevention of ventricular tachycardia in a subject.
A compound for use as claimed in any one of the preceding claims, wherein said compound inhibits PDE2, e.g. human PDE2, with an IC50 value of less than about 100 nM, preferably less than about 50 nM, e.g. less than about 10 nM.
A compound for use as claimed in any one of the preceding claims, wherein said compound is selected from any of the following, their pharmaceutically acceptable salts or prodrugs thereof:
A compound for use as claimed in any one of the preceding claims in the treatment of a subject who has previously suffered a myocardial infarction, a subject who has heart failure, or a subject predisposed to tachycardia, e.g. a subject having a genetic predisposition to catecholaminergic polymorphic ventricular tachycardia (CPVT).
A compound for use as claimed in 12, wherein said subject has an implanted cardiac defibrillator (ICD) and is undergoing treatment with an anti-arrhythmic drug, e.g. a beta-blocker.
A compound for use as claimed in any one of the preceding claims, wherein said subject is a mammalian subject, preferably a human.
A compound for use as claimed in any one of the preceding claims in a combination therapy with one or more cardiovascular drugs, preferably a drug for the treatment of hypertension, heart failure, arrhythmia and/or post infarction myocardial reperfusion syndrome, e.g. wherein said drug is selected from any of the following:
A method of treatment as claimed in 23, wherein said subject has an implanted cardiac defibrillator (ICD) and is undergoing treatment with an anti-arrhythmic drug, preferably a beta-blocker, e.g. a β1-selective beta-blocker such as Metoprolol.
Dependencies are inferred from the claim text.